Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2020

Jun 10, 2020

31801_dirs_2020-06-10_060caef4-696c-4418-b128-f09aaab0cccd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2020-06-09

Reporting Person: KELER TIBOR (Executive VP & CSO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-06-09 Common Stock, par value $0.001 per share P 5000 $2.9908 Acquired 7357 Direct